NCT05172336 is a clinical trial in Fetal Cardiac Disorder, sponsored by Wael Elbanna Clinic.

Who is sponsoring NCT05172336?

NCT05172336 is sponsored by Wael Elbanna Clinic.

What condition does NCT05172336 study?

NCT05172336 studies Fetal Cardiac Disorder.

Is NCT05172336 still recruiting?

NCT05172336 is currently status unknown. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT05172336

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fetal Cardiac Remodeling in Singleton Pregnancies Conceived by Assisted Reproductive Technology (Biopsied and Non-Biopsied ICSI) Versus Those Normally Conceived

Status unknown Last updated 10 October 2023

What this trial tests

trial in Fetal Cardiac Disorder in 111 participants. Status unknown.

Timeline

28 August 2021

Primary endpoint
30 November 2023

30 December 2023

Quick facts

Lead sponsor	Wael Elbanna Clinic
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	111
Start date	28 August 2021
Primary completion	30 November 2023
Estimated completion	30 December 2023
Sites	1 location across Egypt

Conditions studied

Fetal Cardiac Disorder — all drugs for Fetal Cardiac Disorder →

Sponsor

Wael Elbanna Clinic

Who can join

Adults 18 to 49, female only, with Fetal Cardiac Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to assess the presence of fetal cardiac remodeling and dysfunction in singleton pregnancies conceived by assisted reproductive technology (Biopsied and Non-Biopsied ICSI) as compared with those conceived spontaneously (SC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fetal Cardiac Disorder

Currently open trials in the same condition.

NCT07095829 — Prognostic Model of Postnatal Circulation in Pulmonary Atresia-critical Stenosis With Intact Ventricular Septum · recruiting
NCT05386173 — Effect of Fetal Aortic Valvuloplasty on Outcomes · recruiting
NCT03775954 — Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise · recruiting

Other Wael Elbanna Clinic trials

Trials by the same sponsor.

NCT05170230 — The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic · NA · recruiting
NCT05154279 — The Effect of Intramyometrial Injection of Terlipressin Versus Intramyometrial Injection of Carbitocin on Hemoglobin and · NA · unknown
NCT05242783 — The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myome · NA · completed
NCT05266534 — The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myome · NA · recruiting
NCT05050747 — Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05172336 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wael Elbanna Clinic
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing